SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today that Edward F. Brennan, President and Chief Executive Officer, and Gregory J. Tibbitts, Chief Financial Officer, are scheduled to present at the CIBC World Markets 18th Annual Healthcare Conference in New York, NY on Tuesday, November 6, 2007 at 3:40 p.m. ET at the Waldorf-Astoria Hotel.
Management will provide a general corporate update and review of several important milestones, including the recent FDA approval of the Company's Cardiac Cryoablation System for the treatment of atrial flutter and the completion of enrollment of the Company's pivotal clinical trial for atrial fibrillation. CryoCor began selling its Cryoablation System in the fourth quarter of 2007, and is initially targeting placements with thought-leading electrophysiologists in high-volume ablation centers across the U.S. CryoCor is the first company to complete enrollment of a pivotal clinical trial for atrial fibrillation.
A live Web cast and recording of the presentation will be available online from the investor relations page of the Company's corporate Web site at http://www.cryocor.com. The recording will remain available on CryoCor's Web site for at least 30 days following presentation.
CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor has completed enrollment in a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved in the United States for the treatment of right atrial flutter. For more information please visit the Company's website at http://www.cryocor.com
Forward Looking Statements
The statements in this press release that are not descriptions of historical facts are forward-looking statements that are subject to risks and uncertainties. The actual events or results may differ materially from those projected in such forward-looking statements due to a number of factors and the risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company expressly disclaims any intent or obligation to update any of these forward-looking statements.
CryoCor, Inc. The Ruth Group
Gregory J. Tibbitts Nick Laudico / Zack Kubow (investors)
Chief Financial Officer (646) 536-7030 / 7020
(858) 909-2200 email@example.com
Jason Rando (media)
|SOURCE CryoCor, Inc.|
Copyright©2007 PR Newswire.
All rights reserved